Know Cancer

forgot password

Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients With High TNF-alpha on the Efficacy of Pegylated Interferon Alfa-2b/Ribavirin Therapy

Phase 3
18 Years
65 Years
Not Enrolling
Hepatitis C, Chronic

Thank you

Trial Information

Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients With High TNF-alpha on the Efficacy of Pegylated Interferon Alfa-2b/Ribavirin Therapy

Inclusion Criteria:

- Subjects must demonstrate their willingness to participate in the study and comply
with its procedures by signing a written informed consent.

- Subjects must be 18 to 65 years of age.

- HCV genotype 1 (including mixtures of subtypes of genotype 1).

- Naïve to interferon (any formulation) and ribavirin.

- Serum TNF-alpha >300 pg/mL(single measure at Pre-Screen Visit).

- HCV ribonucleic acid (RNA) positive.

- Any alanine aminotransferase (ALT) level.

- Fasting glucose should be 3.8-6.2 mmol/L. Results between 6.3-7.8 mmol/L require a
HbA1c <=8.5%. All diabetic subjects must have an HbA1c <=8.5%, whether on medication
or diet controlled.

- Liver biopsy within 24 months of enrolment demonstrating Stage 0-3 fibrosis (Metavir

- Compensated liver disease with the following minimum hematological, biochemical, and
serological criteria at the screen visit (WNL = within normal limits):

- Hemoglobin values of equal or more than 12 g/dL for females and 13 g/dL for

- White blood cell (WBC) count equal to or more than 3,000/mm**3

- Neutrophil count equal to or more than 1,500/mm**3

- Platelet count equal to or more than 80,000/mm**3

- Total bilirubin WNL

- Indirect bilirubin WNL (unless non-hepatitis related factors such as Gilbert's
disease explain an indirect bilirubin rise). In such cases indirect bilirubin
should be less than or equal to 50 µmol/L

- Albumin WNL

- Serum creatinine WNL

- Women of childbearing potential (includes women who are less than 1 year
postmenopausal and women who become sexually active) must be willing to use an
acceptable method of birth control, deemed acceptable by the investigator, (e.g.,
hormonal contraceptive, medically prescribed intrauterine device (IUD), condom in
combination with spermicidal) or be surgically sterilized (e.g., hysterectomy or
tubal ligation).

- Subjects must understand and be able to adhere to the dosing and visit schedules, and
agree to record, study medication compliance, concomitant medications, and adverse
events accurately and consistently in a daily diary.

Exclusion Criteria:

- Women who are pregnant or nursing.

- Subjects who have not observed the designated washout periods for any of the
prohibited medications.

- Subjects who have used any investigational product within 30 days prior to

- Acute HCV infection defined as infection for <6 months.

- Male partners to/or Heterosexually active women of childbearing potential not
practicing a highly effective form of contraception.

- Positive screening for tuberculosis (TB) or Tuberculin Skin Test > 5mm.

- History or presence of cirrhosis (Stage 4 on Metavir System) and/or complication such
as ascites, bleeding varices or hepatic encephalopathy

- Active hepatitis B virus (HBV) infection (hepatitis B surface antigen [HBsAg]

- Any known pre-existing psychiatric condition that could interfere with the subject's
participation in and completion of the study such as:

- Pre-existing psychiatric condition, including but not limited to moderate to
severe depression, or a history of severe psychiatric disorders, such as
psychosis, suicidal ideation and/or suicidal attempt

- Severe depression includes the following:

- Hospitalization for depression,

- Electro convulsive therapy for depression, or

- Depression that resulted in a prolonged absence from work and/or
significant disruption of daily functions.

- Subjects with uncontrolled hypertension and/or diabetes.

- Alcohol consumption >50 g/day.

- Nonprescription injection drug use in past 6 months.

- HIV antibody positive.

- Previous Infliximab or other anti-TNF treatment, previous interferon; Pegylated
interferon alfa-2b and ribavirin of any form.

- Clinically significant impairment in cardiac or renal function, central nervous
system, pulmonary, immunological, vascular and gastrointestinal disease.

- Current malignancy (other than resected cutaneous basal, squamous cell carcinoma
and/or in situ cervical cancer).

- Use of illicit drugs which, in the investigator's opinion, may interfere with
compliance with the study procedures.

- Any other condition which, in the opinion of a physician, would make the subject
unsuitable for enrollment or could interfere with the subject participating in and
completing the study.

- Have shown a previous immediate hypersensitivity response, including anaphylaxis, to
an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody).

- Have a known allergy to murine proteins or other chimeric proteins.

- Have or have had any of the following infections within 6 months of screening: herpes
zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis,
histoplasmosis, or mycobacteria other than TB.

- Have a transplanted organ (with the exception of a corneal transplant performed > 3
months prior to screening).

- Have a concomitant diagnosis or any history of congestive heart failure (CHF).

- History of noncompliance to medical regimens, or other condition/circumstance that
could interfere with the patient's adherence to protocol requirements (e.g.,
psychiatric disease, lack of motivation, travel, etc).

- Any cause of liver disease other than chronic hepatitis C, including but not limited

- Hemochromatosis

- Alpha-1 antitrypsin deficiency

- Wilson's disease

- Autoimmune hepatitis

- Alcoholic liver disease

- Non-alcoholic steatohepatitis (NASH)

- Drug-related liver disease

- Subject with a positive TST might be enrolled if the diagnosis of tuberculosis is
ruled out. To rule out TB, the following criteria must be met:

- The medical history is negative for symptoms of TB

- The physical examination must reveal no observations that could be related to TB

- The patient has a documented adequate course of treatment for either LTBI or TB at
least 6 months prior to screening

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Proportion of subjects who have achieved sustained virological response (SVR) in the infliximab (induction dose) plus PEGETRON and the PEGETRON groups at 24 weeks post treatment end

Outcome Time Frame:

24 weeks after completion of up to 48 weeks of PEGETRON therapy

Safety Issue:



Canada: Health Canada

Study ID:




Start Date:

July 2005

Completion Date:

June 2011

Related Keywords:

  • Hepatitis C, Chronic
  • pegylated interferon alfa-2b
  • ribavirin
  • infliximab
  • chronic hepatitis C
  • Hepatitis
  • Hepatitis A
  • Hepatitis C
  • Hepatitis C, Chronic